Rahul Mohindar on September 14: Buy Aurobindo Pharma, Biocon & Vedanta-February 2024-www.financetom.com

Market

Rahul Mohindar on September 14: Buy Aurobindo Pharma, Biocon & Vedanta

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Rahul Mohindar on September 14: Buy Aurobindo Pharma, Biocon & Vedanta

Sep 14, 2018 8:22 AM

Rahul Mohindar and Nilesh Shah, MD of Kotak Mahindra AMC, an Independent Market Expert discusses with Prashant Nair and Surabhi Upadhyay their analysis on the technical side of the market as well as specific stocks and sectors.

Rahul Mohindar also spoke at length on Dr.Reddy's Laboratories, Aurobindo Pharma, Biocon & Vedanta.

Disclaimer

: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.

Previous page： Explained | Why global markets are rallying Next page： India can attract $3.5 bn inflows in 2024 as US federal pension fund switches index: IIFL Sec

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Explained | Why global markets are rallying

Nov 15, 2023

A lower-than-expected inflation reading in the US for October sparked a market rally, fueled by hopes that the Federal Reserve's interest rate hike cycle might be concluding, subsequently driving down yields and the dollar index.

India can attract $3.5 bn inflows in 2024 as US federal pension fund switches index: IIFL Sec

Nov 28, 2023

India will be a major beneficiary with potential inflows of $3.4-3.5 billion following a change in the benchmark index by the federal pension fund, according to

The stars are well aligned for emerging markets

Nov 21, 2023

Veteran global investors are optimistic that the convergence of key factors that traditionally shape market dynamics such as favourable interest rates, a stable US dollar, and advantageous oil prices, bode well for emerging markets.

South Korea to ban short-selling of stocks until June 2024

Nov 5, 2023

South Korea started allowing short-selling of stocks on the two indexes in May 2021 while keeping a pandemic-era ban in place for more than 2,000 equities.